Upcoming events – catalysts approach for Catalyst and Oxurion
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Merck and the pitfalls of biopharma success
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
FDA adcom to pronounce on paclitaxel-coated devices
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Deciphera nears its biggest test
The small-molecule oncology player zeroes in on its first commercial opportunity.
Upcoming events – pivotal readouts for Intra-Cellular and Myovant
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
Swiss big pharmas top the research spending tables
Over the past decade Roche and Novartis consistently spent more on R&D than other big pharma groups, while Abbvie and Astrazeneca have added to their budgets.
Upcoming events – Novo takes aim at type 1 diabetes and Aslan wants to roar
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
US big biotechs lag in the opening quarter of the year
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
AACR 2019 – Vitrakvi relapse findings justify Bayer’s interest
The Vitrakvi follow-on LOXO-195 yields results backing both the rationale behind its development and Bayer’s decision to take on full rights.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.